DWA
ADVM

Dorsey Wright & Associates’s Adverum Biotechnologies ADVM Stock Holding History

Dorsey Wright & Associates’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-74
Closed -$16K – 300
2020
Q2 		$16K Hold
74
– – ﹤0.01% 179
2020
Q1 		$7K Buy
+74
New +$8.63K ﹤0.01% 212
2019
Q3 		– Sell
-119
Closed -$14K – 286
2019
Q2 		$14K Buy
+119
New +$9.85K ﹤0.01% 179

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Dorsey Wright & Associates's ADVM Position: Q3 2020 in Review

Dorsey Wright & Associates sold out of Adverum Biotechnologies (ADVM) in Q3 2020, closing a stake of 74 shares — an estimated $16K sold.

Dorsey Wright & Associates first reported a position in ADVM in Q2 2019 and held it in 3 quarters. The position peaked at $16K in Q2 2020. 160 funds tracked by Wall St. Rank hold ADVM as of Q3 2020.

  • Dorsey Wright & Associates reported no remaining Adverum Biotechnologies position as of Q3 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 74 Adverum Biotechnologies shares in Q3 2020, an estimated $16K.
  • Dorsey Wright & Associates first reported a position in Adverum Biotechnologies in Q2 2019 and held it in 3 quarters.
  • Dorsey Wright & Associates's Adverum Biotechnologies position peaked at $16K in Q2 2020.
  • 160 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2020.

Based on Dorsey Wright & Associates's 13F filing for Q3 2020, filed 28 Oct 2020.